WAVY-TV

Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic Low Back Pain

The PP353 clinical trial met the primary endpoint and demonstrated statistically significant, clinically meaningful and durable reduction in pain and disability in patients with chronic Low Back Pain ...
Business Wire

Ferring to Present New Data Analyses at ASPN 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced the presentation of two analyses of data at the ...
Business Wire

SpinalCyte Announces MRI Evidence of Disc Regeneration Following Phase 1/Phase 2 Clinical Trial of CybroCell™ Dermal Fibroblasts

HOUSTON--(BUSINESS WIRE)--MRI analysis of patients who received intradiscal injections of human dermal fibroblasts (HDFs) shows significant improvement in disc height after six months. This is the ...
KRQE Blogs

Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain

London, UK, 07 March 2024 – Persica Pharmaceuticals Ltd, a privately held, clinical stage pharmaceutical company developing an antibiotic formulation for intradiscal injection to treat Chronic Low ...
Medscape

Can Stem Cells Relieve Chronic Low Back Pain?

Allogeneic bone marrow–derived mesenchymal stromal cells (BM-MSCs) are safe but do not show efficacy in treating intervertebral disc degeneration (IDD) in patients with chronic low back pain. The ...
Business Insider

DiscGenics Announces that Cell Therapy IDCT has Passed the Initial Safety Review of its First-in-Human Clinical Trial for Degenerative Disc Disease

SALT LAKE CITY, Jan. 7, 2019 /PRNewswire/ -- , a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with ...